US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TrovaGene, Inc.

1.19

0.0000

Volume:- -

Turnover:- -

Market Cap:13.10M

PE:-0.42

High:1.19

Open:1.19

Low:1.19

Close:1.19

Loading ...

Overview Company News Filings

Company Profile

Company Name:

TrovaGene, Inc.

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://trovageneoncology.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Trovagene, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Trovagene, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TROV/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TROV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TROV\",,,,,undefined,":{"symbol":"TROV","market":"US","secType":"STK","nameCN":"TrovaGene, Inc.","latestPrice":1.19,"timestamp":1588881600000,"preClose":1.19,"halted":8,"volume":0,"delay":0,"floatShares":9635604,"shares":11011100,"eps":-2.8,"marketStatus":"Pre-Mkt","change":0,"latestTime":"05-12 07:47:08 EDT","open":1.19,"high":1.19,"low":1.19,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.8,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1747056600000},"marketStatusCode":1,"symbolChange":{"newSymbol":"CRDF","executeDate":"2020-05-08"},"adr":0,"adrRate":0,"listingDate":1059624000000,"exchange":"NASDAQ","adjPreClose":1.19,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TROV\",,,,,undefined,":{"symbol":"TROV","floatShares":9635604,"roa":"-76.48%","roe":"-188.72%","lyrEps":-2.796607,"shares":11011100,"dividePrice":0,"high":1.19,"amplitude":0,"preClose":1.19,"low":1.19,"week52Low":0.701,"pbRate":"1.79","week52High":3.46,"institutionHeld":0,"latestPrice":1.19,"eps":-2.8,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.8,"open":1.19},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://trovageneoncology.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":0.0287},{"period":"3month","weight":-0.0606},{"period":"6month","weight":-0.0566},{"period":"1year","weight":0.0849},{"period":"ytd","weight":-0.0371}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Trovagene, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Trovagene, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.","exchange":"NASDAQ","name":"TrovaGene, Inc.","nameEN":"TrovaGene, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"TROV\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TROV\",params:#limit:5,,,undefined,":[{"market":"US","date":"2020-05-08","symbol":"TROV","oldSymbol":"TROV","newSymbol":"CRDF","exchange":"NASDAQ","type":"symbolChange","dateTimestamp":1588910400000},{"market":"US","date":"2020-05-05","symbol":"TROV","fiscalQuarterEnding":"2020/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1588651200000,"reportTimeType":"","actualEps":-1.02},{"market":"US","date":"2020-02-27","symbol":"TROV","fiscalQuarterEnding":"2019/12","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1582779600000,"reportTimeType":"","actualEps":-0.51},{"market":"US","date":"2019-11-07","symbol":"TROV","fiscalQuarterEnding":"2019/09","expectedEps":-0.84,"name":null,"time":"","type":"earning","dateTimestamp":1573102800000,"reportTimeType":"","actualEps":-0.71},{"market":"US","date":"2019-08-08","symbol":"TROV","fiscalQuarterEnding":"2019/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1565236800000,"reportTimeType":"","actualEps":-0.79}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TROV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TROV\",market:\"US\",delay:false,,,undefined,":{}}}